Carolyn Bennett on Questions on the Order paper

With respect to rare diseases and disorders: (a) what has the government done to work with the Canadian Agency for Drugs and Technologies in Health to carry out the recommendations in the 2007 Common Drug Review and work with its provincial and territorial Common Drug Review counterparts to establish a specifically designed approach for the review of drugs for rare disorders and for first-in-class drugs; (b) what is the government doing to follow up on the commitment to a national program for drugs and patients with rare disorders resulting from the 2005 pledge by the Minister of Health to consider the creation of an Expensive Drugs for Rare Disorders Program, and after the Health Council of Canada called for the government to re-engage on a national program for expensive drugs with rare diseases; and (c) what has the government done with regards to the recommendations contained in motion M-426 (rare diseases and disorders), which was passed during the 2nd Session of the 39th Parliament?